In This Article:
In the wake of a significant rally in U.S. stocks, fueled by expectations of economic growth and favorable tax policies following the recent election, investors are closely watching how these developments might influence corporate performance. As markets reach new highs, identifying growth companies with substantial insider ownership can offer insights into where those closest to the business see potential value and opportunity amidst evolving economic conditions.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| People & Technology (KOSDAQ:A137400) | 16.4% | 37.3% |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 42.6% |
| Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
| Laopu Gold (SEHK:6181) | 36.4% | 33.9% |
| Medley (TSE:4480) | 34% | 30.4% |
| Seojin SystemLtd (KOSDAQ:A178320) | 31.1% | 49.1% |
| Findi (ASX:FND) | 34.8% | 64.8% |
| Plenti Group (ASX:PLT) | 12.8% | 107.6% |
| Brightstar Resources (ASX:BTR) | 16.2% | 84.6% |
| UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
We'll examine a selection from our screener results.
BioArctic
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) is a Swedish company that develops biological drugs for central nervous system disorders, with a market cap of SEK13.38 billion.
Operations: The company's revenue segment includes SEK299.35 million from biotechnology.
Insider Ownership: 34%
BioArctic's high insider ownership, with major stakeholders controlling 84% of voting rights, aligns with its promising growth trajectory. Recent presentations highlighted their BrainTransporter platform's potential to revolutionize drug delivery across the blood-brain barrier. Analysts forecast BioArctic's revenue to grow by 42.4% annually, significantly outpacing the Swedish market. Despite past losses, profitability is expected within three years. The stock trades at a significant discount to fair value estimates, suggesting potential upside if forecasts materialize.
-
Click here and access our complete growth analysis report to understand the dynamics of BioArctic.
-
Our expertly prepared valuation report BioArctic implies its share price may be lower than expected.
Jiangxi Rimag Group
Simply Wall St Growth Rating: ★★★★★☆
Overview: Jiangxi Rimag Group Co., Ltd. operates medical imaging centers in China and has a market cap of HK$15.80 billion.
Operations: The company's revenue primarily comes from its Medical Labs & Research segment, generating CN¥812.85 million.
Insider Ownership: 24.3%
Jiangxi Rimag Group's insider ownership supports its strong growth prospects, with earnings projected to grow significantly at 71.8% annually, outpacing the Hong Kong market. Despite recent leadership changes and a decline in profit margins from 2.6% to 0.6%, revenue is expected to increase by 30% per year, surpassing market averages. The stock trades slightly below fair value estimates, offering potential if growth forecasts are realized despite current low return on equity projections.